Spss statistics base v22

Descriptive statistics (mean, median, and proportion) were used to summarize baseline patient characteristics and treatment patterns. OS time was calculated from the date of therapy initiation to the date of death. Survival was analyzed using the Kaplan-Meier method, with statistical significance of survival differences assessed using a nonparametric log-rank test. The statistical significance of descriptive differences in study variables and clinical outcomes between the two groups was assessed using t tests and χ² tests, as appropriate, with corresponding P values reported. All statistical analyses were performed using IBM SPSS Statistics Base v22.0 (SPSS, Chicago, IL).

Based on the results of the CheckMate 025 study demonstrating an objective response rate of nivolumab of 26% in patients with mRCC,11 (link) we aimed to test the null hypothesis—response rate of target lesion=26%—versus an alternative hypothesis—response rate of target lesion=65%. Setting α=0.05, 17 patients will be required to achieve 90% power using a two-sided log-rank test.
Summary statistics (mean, median and proportion) were used to describe baseline patient characteristics and treatment patterns. All statistical analyses were carried out using IBM SPSS Statistics Base V.22.0.